PCSK9 and metabolic syndrome: In the China cholesterol education program (CCEP) expert advice for the management of dyslipidemias to reduce cardiovascular risk (2019; China Cholesterol Education Program Working Committee et al., 2020), it is recommended to add PCSK9 inhibitors if the LDL-C goal of <55mg/dl (<1.4mmol/L) is not achieved after 4–6weeks of statin combined with ezetimibe therapy.